Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection.
B-Lymphocytes
/ virology
CRISPR-Cas Systems
/ genetics
Epstein-Barr Virus Infections
/ genetics
Epstein-Barr Virus Nuclear Antigens
/ genetics
Gene Editing
/ methods
Gene Knockout Techniques
/ methods
Herpesvirus 4, Human
/ genetics
Humans
Lymphocyte Activation
/ genetics
Viral Proteins
/ genetics
Virus Latency
/ genetics
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
19
11
2020
accepted:
04
03
2021
revised:
27
04
2021
pubmed:
16
4
2021
medline:
4
8
2021
entrez:
15
4
2021
Statut:
epublish
Résumé
Gene editing is now routine in all prokaryotic and metazoan cells but has not received much attention in immune cells when the CRISPR-Cas9 technology was introduced in the field of mammalian cell biology less than ten years ago. This versatile technology has been successfully adapted for gene modifications in human myeloid cells and T cells, among others, but applications to human primary B cells have been scarce and limited to activated B cells. This limitation has precluded conclusive studies into cell activation, differentiation or cell cycle control in this cell type. We report on highly efficient, simple and rapid genome engineering in primary resting human B cells using nucleofection of Cas9 ribonucleoprotein complexes, followed by EBV infection or culture on CD40 ligand feeder cells to drive in vitro B cell survival. We provide proof-of-principle of gene editing in quiescent human B cells using two model genes: CD46 and CDKN2A. The latter encodes the cell cycle regulator p16INK4a which is an important target of Epstein-Barr virus (EBV). Infection of B cells carrying a knockout of CDKN2A with wildtype and EBNA3 oncoprotein mutant strains of EBV allowed us to conclude that EBNA3C controls CDKN2A, the only barrier to B cell proliferation in EBV infected cells. Together, this approach enables efficient targeting of specific gene loci in quiescent human B cells supporting basic research as well as immunotherapeutic strategies.
Identifiants
pubmed: 33857265
doi: 10.1371/journal.ppat.1009117
pii: PPATHOGENS-D-20-02506
pmc: PMC8078793
doi:
Substances chimiques
Epstein-Barr Virus Nuclear Antigens
0
Viral Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1009117Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS Biol. 2017 Aug 3;15(8):e2001992
pubmed: 28771465
Proc Natl Acad Sci U S A. 2019 Aug 6;116(32):16046-16055
pubmed: 31341086
Genome Res. 2014 Oct;24(10):1719-23
pubmed: 25186908
Lancet. 1964 Feb 1;1(7327):238-40
pubmed: 14086209
Mol Ther. 2018 Feb 7;26(2):456-467
pubmed: 29273498
Nat Commun. 2019 Oct 4;10(1):4543
pubmed: 31586074
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Cell Rep. 2016 Oct 25;17(5):1438-1452
pubmed: 27783955
Genome Res. 2014 Jun;24(6):1012-9
pubmed: 24696461
Nat Commun. 2016 Mar 09;7:10934
pubmed: 26956543
PLoS One. 2008 Jan 23;3(1):e1464
pubmed: 18213373
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
mBio. 2019 Sep 17;10(5):
pubmed: 31530670
PLoS Pathog. 2013 Feb;9(2):e1003187
pubmed: 23436997
J Virol. 2015 Jul;89(14):7248-61
pubmed: 25948739
J Exp Med. 2018 Mar 5;215(3):985-997
pubmed: 29436394
PLoS One. 2014 Mar 21;9(3):e92378
pubmed: 24658332
Front Immunol. 2014 Mar 31;5:137
pubmed: 24744760
Nat Rev Immunol. 2015 Mar;15(3):160-71
pubmed: 25698678
Gene. 2004 Dec 8;343(1):91-7
pubmed: 15563834
Nature. 2014 Mar 6;507(7490):62-7
pubmed: 24476820
mBio. 2021 Mar 30;12(2):
pubmed: 33785626
J Virol. 1995 Jan;69(1):231-8
pubmed: 7983714
Eur J Immunol. 2009 Nov;39(11):3097-109
pubmed: 19784949
Gene Ther. 2006 Jan;13(2):150-62
pubmed: 16136164
Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10437-42
pubmed: 26216948
Sci Rep. 2019 Jun 3;9(1):8218
pubmed: 31160637
Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19500-5
pubmed: 17159137
Proc Soc Exp Biol Med. 1967 Aug-Sep;125(4):1246-50
pubmed: 6042436
Gene Ther. 2009 May;16(5):700-5
pubmed: 19212424
Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5875-9
pubmed: 7597045
PLoS Pathog. 2010 Jun 10;6(6):e1000951
pubmed: 20548956
Sci Rep. 2018 Aug 14;8(1):12144
pubmed: 30108345
Curr Top Microbiol Immunol. 2015;391:61-117
pubmed: 26428372
Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15036-41
pubmed: 12409611
J Virol. 2005 Jul;79(14):8784-92
pubmed: 15994772
J Immunol Methods. 2018 Jun;457:33-40
pubmed: 29614266
Science. 2014 Jan 3;343(6166):80-4
pubmed: 24336569
Cell. 2014 Jun 5;157(6):1262-1278
pubmed: 24906146
Pathogens. 2018 Mar 17;7(1):
pubmed: 29562595
Nat Methods. 2015 Apr;12(4):357-60
pubmed: 25751142
Nat Biotechnol. 2015 Sep;33(9):985-989
pubmed: 26121415
Biomed Res Int. 2014;2014:536482
pubmed: 24689045
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Mol Ther. 2008 Aug;16(8):1427-36
pubmed: 18578012
Cell Stem Cell. 2014 Nov 6;15(5):643-52
pubmed: 25517468
Mol Cell. 2018 Jul 5;71(1):42-55.e8
pubmed: 29979968
Science. 2020 Feb 28;367(6481):
pubmed: 32029687
Methods Mol Biol. 2017;1648:169-176
pubmed: 28766297